Section
This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.
This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.
A randomized trial shows that a six-month personalised community-based physical activity programme sustains physical activity improvements and functional performance post-pulmonary rehabilitation in COPD patients, though other health benefi
This article reviews current evidence and clinical practices for physiotherapy in ICU settings, emphasizing benefits, safety, staffing challenges, and future directions in critical care rehabilitation.
This pilot randomized trial investigates the safety, feasibility, and efficacy of high intensity interval training modalities compared to constant-load endurance training in COPD patients with chronic respiratory failure, revealing promisin
A genomic epidemiological study reveals that mixed infections and heteroresistance are prevalent among multidrug-resistant tuberculosis cases in Shanghai, complicating diagnosis and treatment.
A digital health program significantly increased lung cancer screening rates among high-risk individuals, underscoring digital tools’ potential to improve preventive care.
This article examines the prevalence, risk factors, and diagnostic screening strategies for rheumatoid arthritis-associated interstitial lung disease (RA-ILD) in early rheumatoid arthritis, highlighting age and disease activity as key predi
This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.
The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeut
The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety p
The CARE trial shows that budesonide-formoterol reliever monotherapy significantly reduces asthma attack rates compared to salbutamol in children aged 5-15 years with mild asthma, with comparable safety over 52 weeks.
The BiB trial showed that adding budesonide to surfactant did not reduce bronchopulmonary dysplasia or death in extremely preterm infants but was associated with increased hyperglycemia risk.
Longitudinal data from the French NutriNet-Santé cohort reveal that persistent and increased use of green cleaning products is associated with a modest but significant rise in asthma symptoms, underscoring the need for cautious use and pati
The AS01E-adjuvanted RSVPreF3 OA vaccine demonstrates robust efficacy against RSV-related lower respiratory tract disease over three seasons in adults aged 60+, with a favorable safety profile and promising immunogenicity findings.
This study assesses the safety and immune response of an adjuvanted RSVPreF3 vaccine in adult allogeneic hematopoietic cell and lung transplant recipients, highlighting modest antibody responses but robust CD4+ T-cell activation, supporting
This article reviews a robust UK trial assessing hypertonic saline and carbocisteine in bronchiectasis, revealing no significant reduction in pulmonary exacerbations over 52 weeks, highlighting the need for continued research on mucoactive
Respiratory Syncytial Virus (RSV) poses serious risks to infants and older adults. Since 2023, RSV immunizations have drastically reduced hospitalizations and deaths. This article explains RSV, symptoms, immunization options, and prevention
A large randomized clinical trial demonstrated that the 23-valent pneumococcal polysaccharide vaccine (PPV23) did not significantly reduce fatal or nonfatal acute coronary syndrome and ischemic stroke among middle-aged adults at increased c
We present a case of multifocal cutaneous tuberculosis in a 35-year-old immunocompetent woman, highlighting diagnostic challenges and effective management with standard anti-tubercular therapy.
